Pharvaris N.V. (PHVS) has released an update.
Pharvaris N.V., a late-stage biopharmaceutical company, has reported strong financial results for 2023 including a solid cash position of €391 million, while advancing its clinical programs for deucrictibant, an oral treatment for hereditary angioedema (HAE). The company is currently enrolling patients in a global Phase 3 study for on-demand treatment of HAE and preparing for a Phase 3 study for prophylactic treatment, following a positive end-of-Phase 2 meeting with the FDA. Additionally, Pharvaris has received the UK Innovation Passport for deucrictibant, bolstering its commitment to bringing new treatment options to the HAE community.
For further insights into PHVS stock, check out TipRanks’ Stock Analysis page.